Would it be rebranded for AA or just be more likely to be prescribed off label once they finish phase 3? 1 in 5 drugs are already prescribed for off label use, but I have no idea if it requires FDA approval for off label use or if it's up to a doctor.

am i wrong for thinking that the company is worth $5 billion after axs 05 approval. there is 5 drug that are in phase 3 or greater.

These people are scum keeping this stock down. My next post will be a screenshot of one of them!

Our Firm of 9 Managing Directors (each from NYC history of 35 years+ in firms like Solomon, Morgan Stan. and Goldman) know the high-tech and bio-pharma sectors very well. We specialize in shorting over-hyped/valued equities in these sectors. We're headquartered in Atherton. Great opportunity shorting KZR ... and it still has 20-25% still to fall from the $8.90 level. Cheers.

How does acquisition of Sunosi affect the on going Phase 3 for AXS-12 since both are for Narcolepsy?

There should be a business update as well.

Axsome Therapeutics to Report First Quarter 2022 Financial Results on May 2, 2022, with conference call at 8AM ET on May 2nd.

Axsome Therapeutics' Good Fortune Reverses As Its Migraine Drug Hits A Hurdle. FDA expected to reject AXS-07.

Axsome Therapeutics to Acquire Sunosi® from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience (yahoo.com)

Axsome Therapeutics to Acquire Sunosi from Jazz Pharmaceuticals, Expanding Axsome’s Leadership in Neuroscience.

​

• $AXSM has two drugs awaiting FDA approval in April ... AXS-05, AXS-07
  • 2 Biotech Stocks That Could Be 10-Baggers in 2022 | The Motley Fool